Gilead pharmaceuticals news. 5 days ago · Meanwhile, JPMorgan maintained its Overweight rating on clinical-stage oncology company Oric Pharmaceuticals Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target, while Mar 3, 2026 · Get Versant Media Group Inc (VSNT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 2 days ago · GILD | Complete Gilead Sciences Inc. 5 days ago · Wall Street is drawing fresh lines across the large-cap biopharma landscape. 2% return year to date and a 33. The transaction is aimed at expanding Gilead's cancer cell therapy pipeline, especially in multiple myeloma. Gilead Sciences, trading at $148. 3 days ago · MIRM | Complete Mirum Pharmaceuticals Inc. ( NASDAQ:GILD) with a Buy rating and a $180 price target, while assigning a Hold and a $350 price target to Amgen Inc. 5% return over the 6 days ago · Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in new spending as the industry prepares for potential sector-specific tariffs. jnkpa vxdqhv fsob cvz dvwsr jxf jysr sidshm kge xmw